Functional Brands Finalizes $142.9M Asset Acquisition, Existing Shareholders Face 98% Dilution
summarizeSummary
Functional Brands Inc. has signed a definitive agreement to acquire BullionFX's Alchemy assets for $142.9 million, issuing Series D Preferred Stock that will convert into 98.28% of the company's common stock, leading to massive dilution for current shareholders.
check_boxKey Events
-
Definitive Asset Purchase Agreement Signed
Functional Brands entered into a definitive Asset Purchase Agreement to acquire BullionFX's Alchemy assets, a blockchain-based financial ecosystem, for $142.9 million. This follows a binding Letter of Intent announced on May 11, 2026.
-
Extreme Dilution for Existing Shareholders
The acquisition consideration involves 100,000 shares of newly created Series D Preferred Stock, which will automatically convert into common stock representing 98.28% of the company's outstanding common stock post-conversion.
-
Shareholder Approval for Conversion Post-Closing
The conversion of the Series D Preferred Stock into common shares is contingent on shareholder approval, which will be sought after the closing of the acquisition, not before.
-
Significant Closing Conditions and Financing Needs
The transaction is subject to numerous conditions, including a minimum $10 million equity financing, settlement of existing Series C Preferred Stock and convertible notes (up to $4 million), and resolution of pending litigation.
auto_awesomeAnalysis
This 8-K finalizes the terms of the previously announced Letter of Intent to acquire BullionFX's Alchemy assets. The definitive agreement confirms a highly dilutive transaction where Functional Brands will issue Series D Preferred Stock valued at $142.9 million, which will convert into 98.28% of the company's common stock. This effectively represents a reverse merger, fundamentally altering the company's ownership structure and future direction. The deal is critical for the company, which has a "going concern" warning and recently reported a significant net loss, but comes at an extreme cost to existing shareholders.
At the time of this filing, MEHA was trading at $0.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.3M. The 52-week trading range was $0.06 to $8.00. This filing was assessed with negative market sentiment and an importance score of 10 out of 10.